Skip to content

Scheduled Intranasal Ketamine

Effects of Opioid Requirements With Scheduled Intranasal Ketamine During Admission for Traumatic Pain

Status
Withdrawn
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05671913
Acronym
SINK
Enrollment
0
Registered
2023-01-05
Start date
2023-01-01
Completion date
2026-01-01
Last updated
2023-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Trauma

Brief summary

The purpose of this research is to determine if scheduled intranasal ketamine effects opioid requirements in adult trauma patients with moderate to severe pain in the inpatient setting.

Interventions

DRUGKetamine

Treatment arm

DRUGPlacebo

Control arm

Sponsors

Sanford Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient between aged 18-80 years, present following a traumatic incident, rate pain \> 5 on the numeric rating scale (NSR), and require admission to the hospital.

Exclusion criteria

* \- Patients that arrive at facility intubated * Patients that received Ketamine in the field * Patients less than 18 years old or greater than 80 years * Pregnant or breast-feeding females * Hemodynamic instability defined as need for vasoactive drugs or Systolic blood pressure \>180 * Weight less than 80 pounds or greater than 300 pounds * Glasgow Coma Scale less than 15 * Current acute head injury resulting in unconsciousness * Current or history of eye injury * Current or history of seizures * Facial or nasal fractures that require nasal precautions * Current or history of intracranial hypertension * History of Schizophrenia * BAC (Blood Alcohol Content) greater than 0.08 * Current alcohol abuse * Current drug abuse or positive drug screen * Chronic pain or patients on pain contracts * Inability to assess pain intensity * Contraindications or allergies to the treatment * Patients with hepatic insufficiency * Prisoners * Nursing home residents * Urine drug screen positive for illicit drugs or medications not on their home medication list. * BAC \> 0.08 * Positive pregnancy test

Design outcomes

Primary

MeasureTime frameDescription
Total Morphine Equivalents (TME) throughout hospitalization72 hoursTotal Morphine Equivalents is a standardized way of measuring opioids that patients receive over time. This will be calculated by a member of the research study team utilizing a standardized formula under pharmacies direction. The Medication Administration Record (MAR) will be reviewed to gather administered doses of opioids throughout the participants hospital stay.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026